Discovery of a Novel Series of 7-Azaindole Scaffold Derivatives as PI3K Inhibitors with Potent Activity.

about

Discovery of a Novel Series of 7-Azaindole Scaffold Derivatives as PI3K Inhibitors with Potent Activity.

Item

http://www.wikidata.org/entity/Q48684041

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Discovery of a Novel Series of ...... hibitors with Potent Activity.

@en

Discovery of a Novel Series of ...... hibitors with Potent Activity.

@nl

type

Item

label

Discovery of a Novel Series of ...... hibitors with Potent Activity.

@en

Discovery of a Novel Series of ...... hibitors with Potent Activity.

@nl

prefLabel

Discovery of a Novel Series of ...... hibitors with Potent Activity.

@en

Discovery of a Novel Series of ...... hibitors with Potent Activity.

@nl

P1476

Discovery of a Novel Series of ...... hibitors with Potent Activity.

@en

P2093

Chengbin Yang

http://www.w3.org/2001/XMLSchema#string

Ling-Hua Meng

http://www.w3.org/2001/XMLSchema#string

Mingli Deng

http://www.w3.org/2001/XMLSchema#string

Xi Zhang

http://www.w3.org/2001/XMLSchema#string

Xiaofeng Liu

http://www.w3.org/2001/XMLSchema#string

Yaming Zhou

http://www.w3.org/2001/XMLSchema#string

Yi Wang

http://www.w3.org/2001/XMLSchema#string

Yongtai Yang

http://www.w3.org/2001/XMLSchema#string

Yu Jia

http://www.w3.org/2001/XMLSchema#string

P2860

The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer

Discovery and optimization of a series of benzothiazole phosphoinositide 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) dual inhibitors

Phospshoinositide 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) dual inhibitors: discovery and structure-activity relationships of a series of quinoline and quinoxaline derivatives

Discovery of a potent, selective, and orally available class I phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) kinase inhibitor (GDC-0980) for the treatment of cancer

Discovery of GSK2126458, a Highly Potent Inhibitor of PI3K and the Mammalian Target of Rapamycin

Azaindole-Based Inhibitors of Cdc7 Kinase: Impact of the Pre-DFG Residue, Val 195

The phosphatidylinositol 3-Kinase AKT pathway in human cancer

Targeting the phosphoinositide 3-kinase pathway in cancer

Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity

PI3K and cancer: lessons, challenges and opportunities

P304

875-880

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1021/ACSMEDCHEMLETT.7B00222

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Yun Ling

P577

2017-07-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28835805

http://www.w3.org/2001/XMLSchema#string

P932

5554905

http://www.w3.org/2001/XMLSchema#string